期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 137, 期 1, 页码 18-25出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2016.08.022
关键词
-
类别
资金
- Regeneron
- Sanofi
- MedImmune
- Celgene
- Stiefel/GlaxoSmithKline
- Celsus
- BMS
- Amgen
- Drais
- AbbVie
- Anacor
- AnaptysBio
- Dermira
- Galderma
- Glenmark
- LEO Pharma
- Novartis
- Pfizer
- Vitae
- Mitsubishi Tanabe
- Eli Lilly
- Janssen
- Bristol-Myers Squibb
- Merck
- Grants-in-Aid for Scientific Research [15H05790] Funding Source: KAKEN
Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections. Associations with cardiovascular, neuropsychiatric, and malignant diseases were increasingly reported, but confirmation of their link with atopic dermatitis requires longitudinal studies. Given the possibility of atopic dermatitis-related systemic immune activation, future investigations of new interventions should concurrently examine the impact on these comorbidities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据